title: Clinical experience with exenatide in a routine secondary care diabetes clinic.
abstract: Exenatide use in type 2 diabetes is limited in routine clinical practice. We examined a cross-section of 90 patients. Mean weight and HBA(1c) were 114.9+/-20.6 kg, 10.3+/-2.1% at initiation; 108.0+/-15.3 kg (p<0.0001), 9.0+/-2.1% (p<0.001) at 3 months; 109.2+/-18.2 kg (p<0.0001), 9.5+/-2.3% (p=0.08) at 6 months. Exenatide appears effective in reducing HBA(1c) and weight.
authors.affiliation: Department of Diabetes & Endocrinology, Morriston Hospital, ABM University NHS Trust, Swansea, Wales, UK.
authors.forename: B
authors.initials: B
authors.lastname: Natarajan
authors.forename: M
authors.initials: M
authors.lastname: Edavalath
authors.forename: J
authors.initials: J
authors.lastname: Davies
authors.forename: L
authors.initials: L
authors.lastname: Jenkins
authors.forename: N
authors.initials: N
authors.lastname: Marshall-Richards
authors.forename: D
authors.initials: D
authors.lastname: Evans
authors.forename: D E
authors.initials: DE
authors.lastname: Price
authors.forename: S C
authors.initials: SC
authors.lastname: Bain
authors.forename: J W
authors.initials: JW
authors.lastname: Stephens
mesh_terms: D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D015992:Body Mass Index; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D000077270:Exenatide; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D016896:Treatment Outcome; D014688:Venoms / Q000627:therapeutic use*; D015431:Weight Loss
chemical_list: D001786:Blood Glucose; D000077270:Exenatide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D010455:Peptides; D013453:Sulfonylurea Compounds; D014688:Venoms